DelveInsight Business Research LLP

Latest Healthcare News & Updates: FDA Grants Orphan Drug Status to MDL-101 for LAMA2-CMD Treatment Pfizer’s RSV Vaccine, ABRYSVO, Gains FDA Approval for High-Risk Adults Aged 18-59 Kind's AND017 Secures FDA Orphan Drug Designation for Sickle Cell Disease FDA Fast-Tracks HiberCell’s HC-7366 for Relapsed/Refractory AML Treatment FDA Approves Iterum Therapeutics plc’s ORLYNVAH for Treating Uncomplicated UTIs Get more detailed analysis, at: https://lnkd.in/d4E_tybN #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch

According to DelveInsight, The Global Nicotine Replacement Therapy (NRT) Market is expected to surge with a notable CAGR of ~7% by 2030, with North America leading the growth trajectory. Top companies driving this market include Cipla Johnson & Johnson, Glenmark Pharmaceuticals, Pfizer, Rubicon Research Limited, Sparsha Pharma International Pvt. Ltd., GSK, Philip Morris International, JP Pharma, PL Developments, Dr. Reddy's Laboratories, and Rusan Pharma Ltd., among others. Get detailed insights here: https://lnkd.in/grP3YtK8 #NicotineReplacementTherapy #NRTMarket #MarketGrowth #CAGR #PharmaIndustry #HealthcareMarket #Cipla #JohnsonAndJohnson #Pfizer #GSK #TobaccoFree #QuitSmoking #NicotineGums #DrReddys #NorthAmerica

According to DelveInsight, the sarcopenia market in the 7MM is on track for substantial growth, driven by a steady rise in diagnosed cases, expected to climb from 27.4 million in 2023 through 2034. Leading companies like #Biophytis and #MyMD Pharmaceuticals, Inc. are advancing innovative treatments for sarcopenia, with promising therapies like Sarconeos (BIO101) and MYMD-1 poised to enter the market. These novel therapies are anticipated to address unmet needs in muscle health, offering fresh treatment avenues and contributing to the expansion of the sarcopenia market in the coming years. Get detailed insights here: https://lnkd.in/g2jCj_mQ #Sarcopenia #MarketGrowth #Biophytis #MyMDPharmaceuticals #MuscleHealth #DrugDevelopment #InnovativeTherapies #SarcopeniaTreatment #HealthcareMarket #MuscleHealthSolutions #7MM #BIO101 #MYMD1 #PharmaInnovation #SarcopeniaAwareness

Pfizer’s ABRYSVO has become the first and only RSV vaccine approved for adults under 50, now offering the broadest RSV vaccine coverage for this age group. The updated label, announced on October 22, 2024, includes younger adults considered at higher risk for RSV-related lower respiratory tract disease (LRTD).  While ABRYSVO's approval is a competitive advantage over GSK’s AREXVY, which is approved for individuals 50 and older, its impact remains uncertain as the Centers for Disease Control and Prevention (CDC) has yet to recommend ABRYSVO for a wider age range. Along with ABRYSVO and AREXVY, Moderna’s mRESVIA and Sanofi/AstraZeneca’s BEYFORTUS are also approved for RSV. Other companies, including AstraZeneca, Blue Lake Biotechnology, and Meissa, are advancing additional candidates in various stages of development to enhance the treatment landscape. Get the complete details at: https://lnkd.in/gbWvvpYi

Congratulations, Shristi Dubey Patnaha, on your first work anniversary. Your commitment to excellence has not only enriched our workplace culture but has played a crucial role in driving our company forward. On this occasion, we want to express our deepest gratitude for your hard work, resilience, and unwavering dedication. We are truly fortunate to have you as an essential part of our team and eagerly look forward to continuing our collaboration with you and witnessing your future successes. #workanniversary #workanniversaries #thankyou #dedication #kudos #goingaboveandbeyond #goingtheextramile #zeal #commitment #excellence #positiveattitude #hardwork #focus #appreciation #milestoneachievement #teamsuccess #employeeappreciation

Exosomes are becoming a promising area in therapeutics, with ongoing research focused on exosome-based treatments. These therapies have the potential to transform drug delivery, regenerative medicine, and diagnostic techniques. The effects of exosomes can vary significantly based on the donor cell source, leading to both positive and negative outcomes. In regenerative medicine, especially with incubated cell preparations, exosomes show promise as disease-modifying treatments for autoimmune diseases. However, it's crucial to understand that exosome therapies are not currently FDA-approved and should be used only in research contexts or through submitted FDA Biologics License Applications. Some of the drugs in development include CAP-1002 (Capricor Therapeutics, Inc.), ExoFlo (Direct Biologics), AGLE-102 (Aegle Therapeutics), ILB-202 (ILIAS Biologics Inc.), and BRE-AD01 (BREXOGEN Inc.), among others. For a closer look at these therapies read our blog at: https://lnkd.in/gjmmp3sm

Med-Tech News & Trends: iRhythm Technologies, Inc. Received FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device  Epitel Expanded AI Portfolio With A Fourth FDA 510(k) Clearance for REMI  SeaStar Medical Announced that Enrollment in its Adult Acute Kidney Injury Pivotal Trial had Exceeded the Halfway Point Towards an Interim Analysis Endospan Ltd. Completed the Enrollment of Primary Arm in NEXUS® Aortic Arch Stent Graft TRIOMPHE IDE Clinical Study  Boston Scientific Launched Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System GE HealthCare Announced CareIntellect for Oncology, Harnessing AI to Give Clinicians an Easy Way to See the Patient Journey in a Single View Get more details, at: https://lnkd.in/gbViCv5N #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #medtech #medtechnews

Plasma Protein Therapeutics (PPTs) represent a transformative frontier in medicine, leveraging proteins derived from human plasma to treat rare and chronic diseases. These therapeutics are essential for managing conditions like immune deficiencies, hemophilia, and neurological disorders. Plasma proteins, such as immunoglobulins, clotting factors, and albumin, are crucial for maintaining normal bodily functions, and their therapeutic applications are vast. As research advances, PPTs are also being explored for autoimmune diseases, sepsis, and even COVID-19 treatments. The increasing demand for personalized medicine and biologics is driving innovation, making PPTs a key player in the evolving healthcare landscape. However, challenges such as limited plasma supply, high production costs, and regulatory hurdles continue to affect the industry. Emerging trends include innovations in recombinant technology, which aims to reduce reliance on human plasma, and advancements in manufacturing processes to improve yield and safety. Companies like Octapharma AG, Takeda Pharmaceutical Company Limited, Biotest AG, Grifols, S.A., CSL, Bayer AG, Baxter International Inc., Bio Products Laboratory Limited, Kedrion Biopharma S.p.A, China Biologic Products Holdings Inc, and others are at the forefront of this sector, leading clinical research and expanding global reach. As the need for plasma-derived therapies grows, addressing supply constraints and improving production efficiency will be critical to unlocking the full potential of PPTs. Explore more about plasma protein therapeutics at: https://lnkd.in/dD8Xksuj

Latest Healthcare News & Updates: Gilead Sciences and MSD Reports Phase II Data Showing that Switching to a Once-Weekly Oral Combination of Islatravir and Lenacapavir Maintained Viral Suppression in Adults Through 48 Weeks REGENXBIO Unveils Promising Phase II Data on ABBV-RGX-314 for Bilateral Wet AMD at AAO 2024 U.S. FDA Approves Astellas Pharma' VYLOY for Advanced Stages of Gastric and GEJ Cancers MSD's CAPVAXIVE Shows Promising Immune Response in High-Risk Adults for Pneumococcal Disease FDA Delays Amgen’s LUMAKRAS Colorectal Cancer Approval Decision Until Early 2025 Get more detailed analysis, at: https://lnkd.in/dCpzFQEH #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch

Exciting developments in lung cancer research were unveiled at ESMO 2024! Key insights from the conference highlight significant progress in targeted therapies and combination treatments for non-small cell lung cancer (NSCLC). With advancements from industry leaders like Bristol Myers Squibb and Mirati Therapeutics, we’re witnessing a transformative shift in treatment approaches, particularly for patients with actionable mutations. Dive into our in-depth analysis of the latest abstracts, including promising data on KRAS and EGFR inhibitors, bispecific antibodies, and innovative combination therapies. As the landscape evolves, these breakthroughs are crucial for improving outcomes for NSCLC patients. Stay informed and explore the full insights from ESMO - European Society for Medical Oncology 2024—let’s drive the future of precision oncology together with DelveInsight Business Research LLP! #LungCancer #ESMO2024 #PrecisionOncology #HealthcareInnovation #DelveInsight